Onintza Sagredo, Sara González, and Ilia Aroyo contributed equally to this study.
Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease
Article first published online: 29 DEC 2008
Copyright © 2008 Wiley-Liss, Inc.
Volume 57, Issue 11, pages 1154–1167, 15 August 2009
How to Cite
Sagredo, O., González, S., Aroyo, I., Pazos, M. R., Benito, C., Lastres-Becker, I., Romero, J. P., Tolón, R. M., Mechoulam, R., Brouillet, E., Romero, J. and Fernández-Ruiz, J. (2009), Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease. Glia, 57: 1154–1167. doi: 10.1002/glia.20838
- Issue published online: 1 JUL 2009
- Article first published online: 29 DEC 2008
- Manuscript Accepted: 26 NOV 2008
- Manuscript Received: 24 JUL 2008
- CIBERNED. Grant Numbers: CB06/05/0089, CB06/05/1109
- Santander-UCM. Grant Number: PRR27/05-13975
- MEC. Grant Numbers: SAF2006/11333, SAF2007/61565
- CAM. Grant Number: S-SAL-0261/2006
- US National Institute on Drug Abuse
- Israel Science Foundation
- Socrates-Erasmus Programme
- Programa FPI-Ministerio de Educación y Ciencia
- CB1 and CB2 receptors;
- Huntington's disease;
Cannabinoid agonists might serve as neuroprotective agents in neurodegenerative disorders. Here, we examined this hypothesis in a rat model of Huntington's disease (HD) generated by intrastriatal injection of the mitochondrial complex II inhibitor malonate. Our results showed that only compounds able to activate CB2 receptors were capable of protecting striatal projection neurons from malonate-induced death. That CB2 receptor agonists are neuroprotective was confirmed by using the selective CB2 receptor antagonist, SR144528, and by the observation that mice deficient in CB2 receptor were more sensitive to malonate than wild-type animals. CB2 receptors are scarce in the striatum in healthy conditions, but they are markedly upregulated after the lesion with malonate. Studies of double immunostaining revealed a significant presence of CB2 receptors in cells labeled with the marker of reactive microglia OX-42, and also in cells labeled with GFAP (a marker of astrocytes). We further showed that the activation of CB2 receptors significantly reduced the levels of tumor necrosis factor-α (TNF-α) that had been increased by the lesion with malonate. In summary, our results demonstrate that stimulation of CB2 receptors protect the striatum against malonate toxicity, likely through a mechanism involving glial cells, in particular reactive microglial cells in which CB2 receptors would be upregulated in response to the lesion. Activation of these receptors would reduce the generation of proinflammatory molecules like TNF-α. Altogether, our results support the hypothesis that CB2 receptors could constitute a therapeutic target to slowdown neurodegeneration in HD. © 2008 Wiley-Liss, Inc.